ADC Therapeutics SA Adjustments to Additional Paid in Capital, Warrant Issued
ADC Therapeutics SA (ADCT) reported Adjustments to Additional Paid in Capital, Warrant Issued of $65.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-13
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for the quarter ending 2025-12-31 was $14.61M.
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was $0.00.
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for the quarter ending 2025-06-30 was $50.76M, a 37.47% increase year-over-year.
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $0.00.
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for fiscal 2025 was $65.37M, a 77.04% increase from fiscal 2024.
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for fiscal 2024 was $36.92M.
- ADC Therapeutics SA adjustments to additional paid in capital, warrant issued for fiscal 2022 was $3.71M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued | Adjustments to Additional Paid in Capital, Warrant Issued 1 month | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $14.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $14.61M derived: sum of 2 quarters · filed 2026-03-10 | $65.37M derived: sum of 3 quarters · filed 2026-08-13 | $65.37M 10-K · filed 2026-03-10 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $50.76M derived: sum of 2 quarters · filed 2026-08-13 | $50.76M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $50.76M 10-Q · filed 2026-08-13 | $50.76M 10-Q · filed 2026-08-13 | ||||
| 2025-06-11 | $50.80M 10-K · filed 2026-03-10 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $36.92M derived: sum of 3 quarters · filed 2026-03-10 | $36.92M 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $36.92M derived: sum of 2 quarters · filed 2025-11-10 | $36.92M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $36.92M 10-Q · filed 2025-08-12 | $36.92M 10-Q · filed 2025-08-12 | ||||
| 2024-05-31 | $36.90M 10-K · filed 2026-03-10 | |||||
| 2022-12-31 | $3.71M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |